EA033291B1 - Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии - Google Patents

Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии

Info

Publication number
EA033291B1
EA033291B1 EA201690395A EA201690395A EA033291B1 EA 033291 B1 EA033291 B1 EA 033291B1 EA 201690395 A EA201690395 A EA 201690395A EA 201690395 A EA201690395 A EA 201690395A EA 033291 B1 EA033291 B1 EA 033291B1
Authority
EA
Eurasian Patent Office
Prior art keywords
dosage unit
ramipril
active ingredients
preparation
bisoprolol hemifumarate
Prior art date
Application number
EA201690395A
Other languages
English (en)
Russian (ru)
Other versions
EA201690395A1 (ru
Inventor
Эва Гутине Мольнар
Жольт Жигмонд
Зольтанне Тот
Адам Орбан
Original Assignee
Эгиш Дьёдьсердьяр Зрт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эгиш Дьёдьсердьяр Зрт. filed Critical Эгиш Дьёдьсердьяр Зрт.
Publication of EA201690395A1 publication Critical patent/EA201690395A1/ru
Publication of EA033291B1 publication Critical patent/EA033291B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201690395A 2013-08-16 2014-08-15 Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии EA033291B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1300496A HUP1300496A2 (hu) 2013-08-16 2013-08-16 Stabil kombinációs gyógyszerkészítmény
PCT/HU2014/000072 WO2015022560A1 (fr) 2013-08-16 2014-08-15 Composition pharmaceutique stable contenant du bisoprolol et du ramipril

Publications (2)

Publication Number Publication Date
EA201690395A1 EA201690395A1 (ru) 2016-07-29
EA033291B1 true EA033291B1 (ru) 2019-09-30

Family

ID=89991232

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690395A EA033291B1 (ru) 2013-08-16 2014-08-15 Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии

Country Status (3)

Country Link
EA (1) EA033291B1 (fr)
HU (2) HUP1300496A2 (fr)
WO (2) WO2015022560A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3501502A1 (fr) * 2017-12-20 2019-06-26 Midas Pharma GmbH Compositions pharmaceutiques dosées fixes comprenant de l'amlodipine, du ramipril et de l'atorvastatine
WO2021162562A2 (fr) 2020-02-10 2021-08-19 Adamed Pharma S.A. Composition de ramipril stable et composition à dose fixe comprenant celle-ci
CN115068434B (zh) * 2022-08-03 2023-05-09 昆山龙灯瑞迪制药有限公司 一种雷米普利片的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056442A1 (fr) * 2005-11-07 2007-05-18 King Pharmaceuticals Research & Development, Inc. Compositions de ramipril stabilise en combinaison avec un autre agent actif

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3174844D1 (en) 1980-10-23 1986-07-24 Schering Corp Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
DE3226768A1 (de) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3739690A1 (de) 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
US20030215526A1 (en) 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors
WO2003092729A1 (fr) * 2002-05-03 2003-11-13 Hexal Ag Formulation pharmaceutique stable contenant une statine combinee avec un inhibiteur de l'ace
DK1635792T3 (da) 2003-06-26 2009-06-15 Teva Pharma Stabile farmaceutiske sammensætninger af 2-aza-bicyklo-3.3.0-oktan-3-carboxylsyrederivater
AU2003300692A1 (en) 2003-10-30 2005-05-19 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
GB2394660A (en) 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
WO2005067887A2 (fr) 2004-03-24 2005-07-28 Actavis Group Formulations de ramipril
MX2007005373A (es) 2004-11-05 2007-08-14 King Pharmaceuticals Res & Dev Composiciones estabilizadas de ramipril y metodos para elaborarlas.
CN100374462C (zh) 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
US20070232680A1 (en) 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
CA2647705A1 (fr) 2006-04-19 2007-10-25 Teva Pharmaceutical Industries Ltd. Compositions pharmaceutiques stables de derives de l'acide 2-aza-bicyclo[3.3.0]-octane-3-carboxylique
EP2034966A1 (fr) 2006-06-30 2009-03-18 Alphapharm Pty Ltd. Composition stabilisée comprenant des inhibiteurs de l'eca
JP2010500374A (ja) 2006-08-08 2010-01-07 エーシーシーユー−ブレイク テクノロジーズ，インク． 複数の活性セグメントを含む薬剤の錠剤
WO2008065485A2 (fr) 2006-10-19 2008-06-05 Torrent Pharmaceuticals Limited Compositions pharmaceutiques stables composées d'un bloqueur des canaux calcium et d'un inhibiteur ace
CN101674811B (zh) 2007-02-09 2015-08-19 阿尔法制药有限公司 含有两种或更多种不同物理形态的活性药物成分的剂型
WO2008132756A1 (fr) 2007-05-01 2008-11-06 Lupin Limited Compositions pharmaceutiques stables de ramipril
HU230877B1 (hu) 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
EP2272874A1 (fr) 2009-07-10 2011-01-12 CSL Behring GmbH Rôle de PLD1 dans la formation du thrombus et activation d'intégrine alpha llb béta 3
CN101612403A (zh) 2009-08-13 2009-12-30 王丽燕 含钙拮抗剂、ace抑制剂和他汀类药的药物组合物
CN107441495A (zh) 2012-02-17 2017-12-08 埃吉斯药物私人有限公司 稳定性提高的药物制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056442A1 (fr) * 2005-11-07 2007-05-18 King Pharmaceuticals Research & Development, Inc. Compositions de ramipril stabilise en combinaison avec un autre agent actif

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FETZNER, A. BOHM, S. SCHREDER, S. SCHUBERT, R.: "Degradation of raw or film-incorporated @b-cyclodextrin by enzymes and colonic bacteria", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS., ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM., NL, vol. 58, no. 1, 1 July 2004 (2004-07-01), NL, pages 91 - 97, XP004519832, ISSN: 0939-6411, DOI: 10.1016/j.ejpb.2004.02.001 *
FINSTERER JOSEF ; ST�LLBERGER CLAUDIA ; GELPI ELLEN: "Successful heart failure therapy in mitochondrial disorder with noncompaction cardiomyopathy", THE INTERNATIONAL JOURNAL OF CARDIAC IMAGING, KLUWER ACADEMIC PUBLISHERS, DO, vol. 22, no. 3-4, 25 February 2006 (2006-02-25), Do, pages 393 - 398, XP019392601, ISSN: 1573-0743, DOI: 10.1007/s10554-005-9073-4 *
THERES H P, ET AL.: "Combined treatment with ramipril and metoprolol prevents changes in the creatine kinase isoenzyme system and improves hemodynamic function in rat hearts after myocardial infarction", CARDIOVASCULAR DRUGS AND THERAPY., KLUWER ACADEMIC PUBLISHERS, BOSTON., US, vol. 14, no. 6, 1 January 2000 (2000-01-01), US, pages 597 - 606, XP002983205, ISSN: 0920-3206, DOI: 10.1023/A:1007846311040 *

Also Published As

Publication number Publication date
WO2015022560A1 (fr) 2015-02-19
WO2015022559A1 (fr) 2015-02-19
HUP1600414A2 (hu) 2016-09-28
WO2015022560A8 (fr) 2015-05-14
EA201690395A1 (ru) 2016-07-29
HUP1300496A2 (hu) 2015-03-02
HU231052B1 (hu) 2020-02-28

Similar Documents

Publication Publication Date Title
PH12018500975A1 (en) 7-(thiazol-5-yl) pyrrolopyrimidine compound as tlr7 agonist
MD20140073A2 (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
NZ705578A (en) Coated pharmaceutical composition containing regorafenib
AU2013373885B2 (en) Oxazolidone compound, preparing method and application thereof
MX2019009777A (es) Sistemas y metodos para la fabricacion de tabletas, que incluyen tabletas farmaceuticas.
MX2020007554A (es) Formulacion farmaceutica que comprende esomeprazol y bicarbonato de sodio.
MX2022015606A (es) Comprimidos de liberacion inmediata que contienen un farmaco y procesos para formar los comprimidos.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12014501408A1 (en) Immediate release multi unit pellet system
PH12019500638A1 (en) Composite formed into single layer, comprising candesartan and amlodipine
PH12015501301A1 (en) A pharmaceutical composition containing candesartan cilexetil and amlodipine
EA033291B1 (ru) Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
EA201590474A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ
WO2014125504A3 (fr) Compositions pharmaceutiques de fébuxostat
MX2015015681A (es) Composicion farmaceutica que comprende fingolimod.
MX2016008729A (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
WO2013124832A3 (fr) Composition pharmaceutique à libération contrôlée stabilisée comprenant du gliclazide
RU2013107724A (ru) Фармацевтические композиции монтелукаста и левоцетиризина
WO2016153222A3 (fr) Composition pharmaceutique comprenant un sel de potassium de telmisartan et procédé de préparation associé
WO2012153347A3 (fr) Composition pharmaceutique d'olanzapine de forme 1 à administration par voie orale
PH12016502540A1 (en) Pharmaceutical dosage forms
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM